These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

390 related items for PubMed ID: 18397178

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Polyclonal and monoclonal antibodies for induction therapy in kidney transplant recipients.
    Hill P, Cross NB, Barnett AN, Palmer SC, Webster AC.
    Cochrane Database Syst Rev; 2017 Jan 11; 1(1):CD004759. PubMed ID: 28073178
    [Abstract] [Full Text] [Related]

  • 5. A randomized trial of alemtuzumab versus antithymocyte globulin induction in renal and pancreas transplantation.
    Farney AC, Doares W, Rogers J, Singh R, Hartmann E, Hart L, Ashcraft E, Reeves-Daniels A, Gautreaux M, Iskandar SS, Moore P, Adams PL, Stratta RJ.
    Transplantation; 2009 Sep 27; 88(6):810-9. PubMed ID: 19920781
    [Abstract] [Full Text] [Related]

  • 6. Alemtuzumab induction in deceased donor kidney transplantation.
    Huang E, Cho YW, Hayashi R, Bunnapradist S.
    Transplantation; 2007 Oct 15; 84(7):821-8. PubMed ID: 17984833
    [Abstract] [Full Text] [Related]

  • 7. Alemtuzumab with rapid steroid taper in simultaneous kidney and pancreas transplantation: comparison to induction with antithymocyte globulin.
    Reddy KS, Devarapalli Y, Mazur M, Hamawi K, Chakkera H, Moss A, Mekeel K, Post D, Heilman R, Mulligan D.
    Transplant Proc; 2010 Oct 15; 42(6):2006-8. PubMed ID: 20692393
    [Abstract] [Full Text] [Related]

  • 8. Alemtuzumab induction in kidney transplantation.
    Huang E, Cho YW, Shah T, Peng A, Hayashi R, Bunnapradist S.
    Clin Transpl; 2005 Oct 15; ():343-54. PubMed ID: 17424750
    [Abstract] [Full Text] [Related]

  • 9. Alemtuzumab induction and recurrence of glomerular disease after kidney transplantation.
    Pascual J, Mezrich JD, Djamali A, Leverson G, Chin LT, Torrealba J, Bloom D, Voss B, Becker BN, Knechtle SJ, Sollinger HW, Pirsch JD, Samaniego MD.
    Transplantation; 2007 Jun 15; 83(11):1429-34. PubMed ID: 17565315
    [Abstract] [Full Text] [Related]

  • 10. Induction Therapies in Live Donor Kidney Transplantation on Tacrolimus and Mycophenolate With or Without Steroid Maintenance.
    Tanriover B, Zhang S, MacConmara M, Gao A, Sandikci B, Ayvaci MU, Mete M, Tsapepas D, Rajora N, Mohan P, Lakhia R, Lu CY, Vazquez M.
    Clin J Am Soc Nephrol; 2015 Jun 05; 10(6):1041-9. PubMed ID: 25979971
    [Abstract] [Full Text] [Related]

  • 11. Pilot study of rapid steroid elimination with alemtuzumab induction therapy in kidney and pancreas transplantation.
    Sundberg AK, Roskopf JA, Hartmann EL, Farney AC, Rohr MS, Stratta RJ.
    Transplant Proc; 2005 Mar 05; 37(2):1294-6. PubMed ID: 15848701
    [Abstract] [Full Text] [Related]

  • 12. Alemtuzumab induction in deceased donor kidney transplantation.
    Shin M, Song SH, Kim JM, Kwon CH, Joh JW, Lee SK, Kim SJ.
    Transplant Proc; 2011 Mar 05; 43(6):2365-78. PubMed ID: 21839271
    [Abstract] [Full Text] [Related]

  • 13. Infectious complications associated with alemtuzumab use for allogeneic hematopoietic stem cell transplantation: comparison with anti-thymocyte globulin.
    Park SH, Choi SM, Lee DG, Choi JH, Yoo JH, Kim SH, Kim HJ, Cho SG, Eom KS, Lee JW, Min WS, Shin WS, Kim CC.
    Transpl Infect Dis; 2009 Oct 05; 11(5):413-23. PubMed ID: 19708893
    [Abstract] [Full Text] [Related]

  • 14. Influence of induction modality on the outcome of deceased donor kidney transplant recipients discharged on steroid-free maintenance immunosuppression.
    Sureshkumar KK, Thai NL, Hussain SM, Ko TY, Marcus RJ.
    Transplantation; 2012 Apr 27; 93(8):799-805. PubMed ID: 22290269
    [Abstract] [Full Text] [Related]

  • 15. Interleukin-2 receptor antibody reduces rejection rates and graft loss in live-donor kidney transplant recipients.
    Lim WH, Chang SH, Chadban SJ, Campbell SB, Dent H, Russ GR, McDonald SP.
    Transplantation; 2009 Nov 27; 88(10):1208-13. PubMed ID: 19935375
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Acute Rejection Rates and Graft Outcomes According to Induction Regimen among Recipients of Kidneys from Deceased Donors Treated with Tacrolimus and Mycophenolate.
    Tanriover B, Jaikaransingh V, MacConmara MP, Parekh JR, Levea SL, Ariyamuthu VK, Zhang S, Gao A, Ayvaci MUS, Sandikci B, Rajora N, Ahmed V, Lu CY, Mohan S, Vazquez MA.
    Clin J Am Soc Nephrol; 2016 Sep 07; 11(9):1650-1661. PubMed ID: 27364616
    [Abstract] [Full Text] [Related]

  • 18. Alemtuzumab and minimization immunotherapy in kidney transplantation: long-term results of comparison with rabbit anti-thymocyte globulin and standard triple maintenance therapy.
    Zachariah M, Nader ND, Brar J, Singh N, Venuto R, Patel S, Said M, Laftavi MR, Pankewycz O.
    Transplant Proc; 2014 Sep 07; 46(1):94-100. PubMed ID: 24507032
    [Abstract] [Full Text] [Related]

  • 19. Interleukin-2 receptor antagonist compared with antithymocyte globulin induction therapy in kidney transplantation from donors after cardiac death.
    Peng W, Liu G, Xie W, Huang H, Wu J, Shou Z, Chen J.
    Int J Clin Pract Suppl; 2015 May 07; (183):23-8. PubMed ID: 26177071
    [Abstract] [Full Text] [Related]

  • 20. Comparison of alemtuzumab vs. antithymocyte globulin induction therapy in primary non-sensitized renal transplant patients treated with rapid steroid withdrawal.
    Saull HE, Enderby CY, Gonwa TA, Wadei HM.
    Clin Transplant; 2015 Jul 07; 29(7):573-80. PubMed ID: 25711849
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.